Nanopharmaceuticals are beginning to demonstrate their capacity to place the drugs directly in the tumor, where they will do the most good, rather than let them roam freely in the body.
The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer.
Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer therapy has been severely limited. “It was so toxic that it caused death,” and researchers gave up on it, explains Scott McNeil, director of the Nanotechnology Characterization Lab at the Frederick National Laboratory for Cancer Research.
That was back in the 1990s. Today, TNF-alpha is a prime example of how to safely and effectively deliver toxic substances to cancer cells through the use of nanotechnology.
McNeil’s lab, part of the federally funded research and development center operated by SAIC-Frederick for the National Cancer Institute, worked with a drug company to reformulate TNF-alpha by coupling it with gold nanoparticles. Using the nanotechnology-enhanced protein, it appears possible to safely inject up to three times the amount that had been lethal with previous versions. The modified drug has been through a Phase 1 clinical trial and is entering Phase 2.
In McNeil’s lab, and for other scientists using nanotechnology for drug delivery, stories like this one are increasingly common. Researchers are looking to accelerate the development of potential nanotechnology drugs for cancer by exploring ways to reduce side effects and make treatments hit their targets more effectively. This can mean using nanotechnology to reformulate drugs that may have failed in previous clinical trials. In some cases, by attaching a nanoparticle to an existing drug, researchers may not only be able to lower its toxicity, but they may also see significant life expectancy gains for patients.
Many cancer drugs are approved based on how long they delay the progression of disease. Some drugs on the market “only improve life expectancy by maybe five weeks,” says McNeil. He sees nanomedicine as a potential game-changer for cancer drugs in the future.
McNeil, both a chemist and biologist, has spent the majority of his career working in nanotechnology, but when he was asked to apply his expertise to find better drugs for cancer, he was skeptical. “My professional career was mostly military,” says the former Army officer. “I was using nanotech for military applications at SAIC, using quantum dots to see if you scatter things, where they land. I got a call out of the blue in December of 2003 and the message was, ‘We want to use nanotech for cancer applications.’ I thought, ‘What are they thinking? You are going to put a cadmium quantum dot in a human? There is no way!’ I discounted it at first and I actually ignored the emails, hoping it would go away.”
But it did not go away. In fact, much has changed in the last 10 years. Now, nanopharmaceuticals are beginning to demonstrate their capacity to place the drugs directly in the tumor, where they will do the most good, rather than let them roam freely in the body. A drug is attached to a nanoparticle, which is often a tiny little sphere. To put it in perspective, a nanometer is one billionth of a meter; the width of a single strand of hair is about 10,000 nanometers. The nanoparticle is small enough to flow through blood vessels and into a tumor, where the particle dissociates, and the drug is released. In the end, the goal of nanomedicine is that the only part of the body affected by the drug is the tumor, the area of need.
McNeil’s Nanotechnology Characterization Lab was founded in 2004 in collaboration with the Food and Drug Administration and the National Institute of Standards and Technology. There is one thing the lab does not do: develop nanotechnology drugs. Instead, researchers there—ranging in expertise from cancer biology and toxicology to chemistry, immunology, and physics—help investigators from around the world create the best drugs possible. “We help investigators get from proof of concept, where they are generating a few tens of milligrams of material and get into clinical trials, where they are going to need kilograms of materials,” say McNeil. “That translational research, as we call it, is absolutely germane to getting into clinical trials.”
The majority of scientists who apply for assistance from the NCL are seeking FDA approval for their nanotech drugs but they don’t have the resources to optimize their formula. The NCL can help. “We help them understand what is involved with their particle because they don’t have the tools that we have to be able to characterize,” says McNeil. “They may have a nice picture or cartoon of it but until they see our electron micrographs, they don’t know what it looks like.”
The Nanotechnology Characterization Lab serves two purposes. After a molecule has been through the NCL’s assay cascade which consists of a set of tests that evaluate the preclinical toxicology, pharmacology, and efficacy of nanoparticles, the NCL is able to offer an evaluation. “The investigator is going to need $40 million dollars to get into Phase 2 trials. Investigators need to justify the investment. We help them generate data they need to further their work and then we serve as a third-party evaluation.” That is crucial, McNeil says, for an investigator seeking funding. “A venture capital company can come to us and say, ‘Well, what do you really think of this? Let’s see your data, and explain it and defend it.’ We, obviously, cannot endorse it but we can discuss the data in the context of what they are trying to do. That really holds a lot of weight.”
Consider the example of Abraxane (paclitaxel), which was approved for use by the FDA in 2005. Abraxane, a variably toxic but widely prescribed cancer drug, has been enhanced by attaching it to a nanoparticle, thereby creating a new, targeted treatment. “Because of the size and the binding to a different receptor, that drug now has decreased toxicity compared to the former drug. For the nanoparticle-Abraxane conjugate toxicity is very marginal, at least for immunotoxicity and hypersensitivity,” says McNeil.
The Latest Bing News on:
- Particle Therapy Market Overview, High Growth Opportunities, Segmentation, Trends By 2022-2030on June 17, 2022 at 2:00 am
Transparency Market Research (TMR) anticipates that the particle therapy market features fragmented vendor landscape owing to a large number of key players operating in the market. Varian ...
- Nanopharmaceuticals Market Industry Growth, Competitors Analysis, New Technology, Trends and Forecast 2022 – 2027on June 15, 2022 at 3:30 am
Nanopharmaceuticals are revolutionizing medical science by leveraging nanomedicine to render effective healthcare, especially in developing countries. The technology is yet in evolution stages and ...
- Polymer–Drug Conjugates for Novel Molecular Targetson June 8, 2022 at 5:00 pm
† PEG-Naloxol (NKTR-118) in Phase II clinical trials. Clinical benefit has already been demonstrated with polymer–drug conjugates bearing classical chemotherapeutic agents. The future of ...
- Global Nanopharmaceuticals Market Insight 2027 | Expected to Reach USD 64460 Million | Growing at a CAGR of 13% | During Forecast Period 2022-2027on May 20, 2022 at 5:52 am
May 20, 2022 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this Nanopharmaceuticals industry." Global "Nanopharmaceuticals Market" (2022-2027) Insight ...
- Interview: An Architectural Journey: From Trees, Dendrons/Dendrimers to Nanomedicineon May 17, 2022 at 5:00 pm
I expect to see a long list of clinical approvals for dendrimer-based nanopharmaceuticals and devices after the current pending Phase III approval for dendrimer-based microbicides by Starpharma ...
- Meet Our Residentson May 15, 2022 at 6:27 pm
I was raised in Annapolis, Maryland and graduated with a degree in chemical engineering from the University of Delaware before earning my PhD in Biomolecular Engineering at Johns Hopkins University ...
- New Materials: Towards a History of Consistencyon March 17, 2021 at 11:42 am
Antibacterial nanosocks, highly durable nanopaints and newly efficacious nanopharmaceuticals have also reached markets over the last decade, each bringing some perceived enhancement in product ...
The Latest Google Headlines on:
The Latest Bing News on:
- Nanopesticide Market Size In 2022 with Top Countries Data : What is the growth rate of the Industry? | In-Depth Analysis with 95 Report Pageson June 27, 2022 at 12:28 am
Nanopesticide Market In 2022 (Short Description) : Nanopesticides are pesticides whose formulation uses nanotechnology ...
- Nanotech Daily News Service - ResearchAndMarkets.comon June 24, 2022 at 5:12 am
The “Nanotech Daily News” newsletter has been added to ResearchAndMarkets.com’s offering. Nanotech Daily News brings together in one d ...
- ECU researchers explore new tech for treating COVID viruson June 24, 2022 at 12:30 am
Two East Carolina University researchers studying how nanotechnology could treat bacterial-based illnesses have discovered it could possibly treat COVID-19 and similar viruses.
- Using microbrewery waste to synthesize carbon quantum dotson June 22, 2022 at 10:32 am
For a few years now, spent grain, the cereal residue from breweries, has been reused in animal feed. This material could also be used in nanotechnology. Professor Federico Rosei's team at the Institut ...
- ECU researchers find potential COVID-19 treatment with new nanotechnologyon June 21, 2022 at 6:38 pm
A pair of researchers at East Carolina University Brody School of Medicine have discovered that new nanotechnology may have therapeutic benefits in the treatment of ...
- When the world of nanotechnology and microbreweries meeton June 21, 2022 at 5:00 pm
Professor Federico Rosei’s team at the Institut national de la recherche scientifique (INRS) has shown that microbrewery waste can be used as a carbon source to synthesize quantum dots. The work was ...
- Nanotechnology in Drug Delivery Market Report 2022-2032on June 21, 2022 at 12:33 am
Reportlinker.com announces the release of the report "Nanotechnology in Drug Delivery Market Report 2022-2032" - The Nanotechnology in Drug Delivery Market Report 2022-2032: This report will prove ...
- Nanotechnology Enabled Cancer Breakthroughson June 16, 2022 at 9:17 am
The potential of nanotechnology for cancer research has been tremendous for the medical field, leading to significant improvements in diagnostics and therapeutics. Image Credit: Buravleva ...
- Can We Help?: Exploring nanotechnologyon June 16, 2022 at 3:53 am
Peter Binks, CEO of Nanotechnology Victoria, answers the question 'How does nanotechnology work?' Discover what nanotechnology is and see several examples in action, such as scratch-resistant paint ...
- ENTOD launches nanotechnology-based under-eye product in Indiaon June 15, 2022 at 12:47 am
The eye gel is based on an innovative plant-based bio cellular formula containing vitamin A+ C+ E complex, anti-aging antioxidants, skin brightening a..